Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 46

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 46
---
 the Merger.

Risks Related to MIRA after Completion of the Merger

MIRA may not be able to integrate SKNY’s development activities into its own operations or manage the combined business effectively, and many of the anticipated synergies and other benefits of acquiring SKNY may not be realized or may not be realized within the expected time frame.

MIRA and SKNY entered into the Merger Agreement with the expectation that the Transaction would result in various benefits, including, among other things, operating efficiencies, synergies and cost savings. Achieving the anticipated benefits of the Merger is subject to a number of uncertainties, including whether the development efforts of SKNY can be integrated in an efficient and effective manner.

It is possible that the integration process could take longer than anticipated or that the management of the combined business could be more difficult than expected, and could result in the disruption of ongoing businesses, processes, systems and business relationships, inconsistencies in standards, controls, procedures, practices, policies and compensation arrangements, higher than expected costs or difficulties in achieving anticipated synergies, business opportunities and growth prospects from the Merger, any of which could adversely affect MIRA’s ability to achieve the anticipated benefits of the Merger. MIRA’s results of operations could also be adversely affected by any issues attributable to either company’s operations that arise or are based on events or actions that occur before the Closing. The integration of SKNY’s development work is subject to a number of risks and uncertainties, and no assurance can be given that the anticipated benefits of the Merger will be realized or, if realized, the timing of their realization. Failure to achieve these anticipated benefits could adversely affect MIRA and the future businesses of SKNY and/or MIRA as well as MIRA’s financial condition, results of operations and prospects.

| 22 |

Uncertainties associated with the Merger may cause a loss of management personnel and other key employees, and MIRA SKNY may have difficulty attracting and motivating management personnel and other key employees, which could adversely affect the future businesses and operations of MIRA.

Both MIRA and SKNY are dependent on the experience and industry knowledge of their respective management personnel and other key employees to execute their business plans. MIRA’s success after the completion of the Merger will depend in part upon the ability of MIRA to attract, motivate and retain management personnel and other employees to pursue the development of the MIRA and SKNY therapies. Prior to completion of the Merger, current and prospective employees of MIRA may experience uncertainty about their roles